Last Updated: November 16, 2026

List of Excipients in Branded Drug SIGNIFOR LAR

« Back to Dashboard


Signifor LAR Excipient Strategy and Commercial Opportunities

Last updated: September 6, 2026

Signifor LAR is a long-acting injectable formulation of pasireotide pamoate developed by Novartis for acromegaly and Cushing’s disease. Its commercial value rests on a biodegradable microsphere delivery system rather than on the active ingredient alone. The key excipient platform uses a poly(lactide-co-glycolide), or PLGA, matrix with mannitol, sodium carboxymethylcellulose and poloxamer 188. The principal commercial opportunities are improved reconstitution, lower injection burden, differentiated depot release, device integration and generic or follow-on development.

What excipients are used in Signifor LAR?

Signifor LAR is supplied as a powder that is reconstituted before intramuscular injection. The formulation contains pasireotide pamoate and a biodegradable polymer matrix.

Component Functional role Commercial relevance
Pasireotide pamoate Active pharmaceutical ingredient Somatostatin receptor ligand used in acromegaly and Cushing’s disease
PLGA Biodegradable depot-forming polymer Controls release over an extended period after intramuscular injection
Mannitol Bulking and matrix-support excipient Supports cake structure and powder handling
Sodium carboxymethylcellulose Suspending and viscosity-modifying agent Helps maintain uniformity after reconstitution
Poloxamer 188 Surfactant and wetting agent Reduces aggregation and improves dispersion of microspheres
Sterile diluent Reconstitution medium Determines preparation time, syringeability and dose uniformity

The US prescribing information identifies the formulation as a depot suspension for intramuscular administration. It is not an aqueous ready-to-inject solution. That distinction creates both technical barriers and commercial opportunity.[1]

How does the PLGA matrix control Signifor LAR release?

PLGA degrades through hydrolysis of ester bonds. The resulting molecular-weight reduction, water penetration and polymer erosion release pasireotide from the microsphere matrix. Release performance depends on:

  • Lactide-to-glycolide ratio
  • Polymer molecular weight
  • Polymer end-group chemistry
  • Particle-size distribution
  • Drug loading
  • Porosity and internal morphology
  • Residual solvent
  • Manufacturing temperature and drying conditions

A manufacturer seeking to reproduce the product must match more than the nominal excipient list. The critical quality target is the in vitro and in vivo release profile, including early burst release, sustained release and terminal release behavior.

What is the formulation strategy behind Signifor LAR?

Signifor LAR uses a depot approach that reduces administration frequency relative to short-acting pasireotide. The product is administered by intramuscular injection, generally at four-week intervals, subject to dose selection and clinical management.[1]

The formulation strategy addresses three requirements:

  1. Maintain pasireotide at therapeutic concentrations over an extended interval.
  2. Produce a reconstituted suspension that can be delivered through an injection needle.
  3. Preserve dose uniformity despite the physical instability risks associated with polymeric microspheres.

This approach shifts development risk from conventional solution stability to complex product performance. The main risks include incomplete wetting, clumping, settling, needle blockage, inconsistent dose withdrawal and variability in polymer degradation.

Which excipient attributes are most important?

The highest-value excipient attributes are polymer grade and surfactant-polymer compatibility.

PLGA selection determines the release window and can affect local tolerability. A higher glycolide content generally increases hydrophilicity and may accelerate degradation, while a higher lactide content tends to produce a more hydrophobic and slower-degrading matrix. The actual outcome depends on polymer molecular weight, particle morphology and drug-polymer interactions.

Sodium carboxymethylcellulose contributes to suspension stability but can increase viscosity. That creates a tradeoff between sedimentation control and injection force. Poloxamer 188 improves wetting and dispersion but may affect interfacial behavior, particle aggregation and release performance.

Mannitol has limited pharmacological significance but can be important to powder morphology, bulk density and reconstitution behavior. Substitution with another bulking agent could alter cake structure, residual moisture and microsphere recovery.

What commercial opportunities exist for Signifor LAR excipients?

The strongest commercial opportunities are in formulation-enabling technologies rather than simple excipient substitution.

Ready-to-use or simplified reconstitution systems

Signifor LAR requires healthcare-professional preparation. A dual-chamber syringe, prefilled cartridge or closed-vial transfer system could reduce preparation steps and lower the risk of dosing errors.

Potential product concepts include:

  • Dual-chamber prefilled syringe
  • Vial adapter with integrated diluent transfer
  • Preassembled reconstitution device
  • Low-dead-volume syringe
  • Needle-compatible delivery system
  • Standardized mixing system with controlled agitation

A device change could improve administration efficiency without changing the active ingredient. It would still require assessment of container closure, extractables and leachables, particle integrity, dose recovery and injection performance.

Lower injection force

The reconstituted depot suspension must pass through a needle with acceptable force. Opportunities exist to optimize:

  • Microsphere size distribution
  • CMC concentration
  • Surfactant level
  • Suspension solids content
  • Diluent volume
  • Needle gauge
  • Mixing energy

A formulation that maintains suspension uniformity at lower viscosity could improve administration. This is commercially relevant in outpatient specialty care, where preparation time and injection handling affect clinic workflow.

Improved dose uniformity

Microsphere suspensions can settle rapidly after reconstitution. A more robust suspension system could reduce variability between the first and last dose withdrawn from a vial.

Potential approaches include:

  • Narrower particle-size distribution
  • Controlled particle surface properties
  • Alternative grades of sodium carboxymethylcellulose
  • Low-level wetting-agent optimization
  • Modified vial geometry
  • Agitation instructions supported by physical characterization

These improvements could support a differentiated product, but they may also create a new regulatory burden if they alter release kinetics or local tolerability.

Extended dosing intervals

A formulation that extends treatment beyond four weeks could offer a commercially meaningful product profile. The main technical challenge is controlling the initial release burst while maintaining predictable terminal release.

Possible approaches include:

  • Higher-molecular-weight PLGA
  • Modified lactide-to-glycolide ratios
  • Polymer blends
  • Drug-polymer complexation
  • Multimodal microsphere populations
  • Larger or denser microspheres
  • Alternative depot technologies

An extended-interval product would likely require new clinical exposure and efficacy data. It would be a lifecycle-management product rather than a straightforward generic substitution.

What formulation patents could protect a Signifor LAR competitor?

Formulation protection can cover the composition, process, release profile, particle characteristics and administration system.

Protection area Potential claim subject
Composition Pasireotide pamoate in a defined PLGA matrix with specified excipient ranges
Polymer attributes Lactide:glycolide ratio, molecular weight, end-group chemistry
Particle characteristics Size distribution, morphology, porosity and drug loading
Manufacturing Emulsification, solvent removal, drying and sterilization processes
Release profile Burst release, cumulative release or pharmacokinetic parameters
Reconstitution Diluent volume, mixing time, suspension stability and dose recovery
Delivery device Prefilled systems, transfer devices and needle configurations
Method of use Extended-release treatment regimens for acromegaly or Cushing’s disease

The most defensible claims generally combine several variables rather than relying on a broad statement that pasireotide is contained in PLGA. A competitor may avoid a composition claim by changing polymer grade or particle morphology while retaining the same therapeutic concept.

When does Signifor LAR lose exclusivity?

Signifor LAR’s exclusivity is determined by multiple rights, not one date. Relevant categories include:

  • Active-ingredient and compound patents
  • Depot formulation patents
  • Manufacturing-process patents
  • Method-of-use patents
  • FDA regulatory exclusivity
  • Pediatric exclusivity, if granted
  • Patent-term extension
  • Patent-term adjustment
  • Settlement restrictions
  • Country-specific rights

Signifor LAR received FDA approval for acromegaly in 2014 and for Cushing’s disease in 2018.[1,2] The FDA approval dates do not establish patent expiration dates. Patent expiry must be determined patent by patent and jurisdiction by jurisdiction.

A commercial entrant should distinguish between expiry of the active-ingredient patent and expiry of later-issued formulation or method-of-use patents. A product may be technically reproducible after a basic compound patent expires but remain exposed to formulation or use claims.

What is the Orange Book status of Signifor LAR?

Signifor LAR is an FDA-approved prescription drug and its relevant patents, exclusivity and use codes must be evaluated through the FDA Orange Book and associated patent records.[3] Orange Book analysis is particularly important for an ANDA applicant because listed patents can trigger Paragraph IV notification and patent litigation.

For a generic or follow-on entrant, the main questions are:

  • Which patents are listed against the specific Signifor LAR strengths?
  • Do the listings cover the formulation, method of use or both?
  • Are any listed patents expired, delisted or subject to a statutory stay?
  • Do the use codes correspond to all approved indications?
  • Can a proposed label carve out a patented indication?
  • Does the proposed product require a Paragraph IV certification?

A Paragraph IV challenge would be difficult if the entrant must demonstrate equivalence to a complex microsphere depot. The legal case would likely involve both patent validity and product-performance evidence.

Which companies are challenging Signifor LAR?

No biosimilar pathway applies to Signifor LAR because pasireotide is a chemically synthesized small molecule, not a biologic. Potential competitors would generally pursue an ANDA or, for a materially different depot formulation, a 505(b)(2) application.

The most likely competitive groups are:

  • Generic injectable manufacturers with microsphere capability
  • Specialty pharmaceutical companies focused on endocrine disorders
  • Contract development and manufacturing organizations with PLGA expertise
  • Device companies developing reconstitution systems
  • Specialty firms pursuing longer-acting somatostatin analogues

A conventional pasireotide solution would not necessarily substitute for Signifor LAR commercially. The long-acting depot profile is a central part of the product’s value proposition.

How does Signifor LAR compare with competing endocrine drugs?

Product Active ingredient Delivery Main competitive distinction
Signifor LAR Pasireotide pamoate Monthly intramuscular depot Broad somatostatin receptor activity; approved for acromegaly and Cushing’s disease
Signifor injection Pasireotide diaspartate Subcutaneous injection Short-acting pasireotide option
Sandostatin LAR Octreotide acetate Monthly intramuscular depot Established acromegaly and neuroendocrine tumor product
Somatuline Depot Lanreotide Deep subcutaneous depot Administration without conventional intramuscular injection
Pegvisomant Pegvisomant Subcutaneous injection Growth-hormone receptor antagonist for acromegaly

Signifor LAR competes against established long-acting endocrine therapies. Its formulation technology must therefore deliver a practical advantage, not merely reproduce pasireotide exposure.

What generic entry risks exist for Signifor LAR?

The principal entry risks are technical and legal.

Technical risks

  • Inability to match the in vitro release profile
  • Different microsphere morphology
  • Excessive initial burst release
  • Inconsistent suspension after reconstitution
  • Needle blockage or high injection force
  • Particle aggregation during storage
  • Residual solvent or moisture variability
  • Local injection-site reactions
  • Inadequate stability after reconstitution

Regulatory risks

Complex injectable products require more extensive characterization than conventional immediate-release tablets. FDA review may focus on sameness of dosage form, route, strength, inactive ingredients and performance characteristics. A change in excipient concentration or polymer properties may require additional clinical justification.

Legal risks

Even if the active compound is no longer protected, formulation and method-of-use patents can delay entry. An ANDA applicant may face a 30-month stay following patent litigation, subject to the specific statutory and procedural circumstances.[4]

What manufacturing and intellectual-property barriers protect Signifor LAR?

The manufacturing process is a significant barrier because the product depends on reproducible microsphere formation. Critical process variables include emulsification energy, solvent extraction, drying conditions, particle classification, aseptic processing and filling.

Scale-up can change particle size and porosity even when nominal process parameters remain constant. The commercial manufacturing advantage may therefore reside in process control, analytical methods and accumulated product knowledge.

Important analytical methods include:

  • Laser diffraction for particle-size distribution
  • Microscopy for morphology
  • Residual-solvent testing
  • Karl Fischer moisture analysis
  • Drug-loading assay
  • In vitro release testing
  • Reconstitution time
  • Suspension uniformity
  • Syringeability and injection-force testing
  • Sterility and endotoxin testing

These methods can support process patents, trade secrets or regulatory differentiation.

What is the revenue exposure for Signifor LAR?

Novartis does not generally disclose standalone global revenue for Signifor LAR as a separate product line in its public annual reporting. Revenue exposure should therefore be assessed using prescription volume, treatment duration, geographic pricing, indication mix and the share of patients receiving monthly depot treatment rather than short-acting pasireotide.

The highest-value commercial segments are likely patients requiring chronic endocrine management, particularly those who remain inadequately controlled or intolerant on other somatostatin analogues. The product’s economic sensitivity includes clinic administration costs, injection frequency, reimbursement, specialty-pharmacy distribution and the availability of competing long-acting products.

How strong is the Signifor LAR patent estate?

The estate is strongest where patent claims combine the active ingredient with specific depot architecture, release behavior and manufacturing parameters. Broad claims covering only pasireotide or generic PLGA use are more vulnerable to prior-art and obviousness challenges.

A competitor’s freedom-to-operate analysis should separate:

  1. Composition claims.
  2. Microsphere and release-profile claims.
  3. Manufacturing claims.
  4. Reconstitution and device claims.
  5. Acromegaly method-of-use claims.
  6. Cushing’s disease method-of-use claims.

The commercial strength of the estate depends on surviving claims that read on the actual product, not merely on the number of issued patents.

Key Takeaways

  • Signifor LAR is a PLGA-based pasireotide pamoate depot suspension.
  • The core excipient system includes PLGA, mannitol, sodium carboxymethylcellulose and poloxamer 188.
  • The most attractive commercial opportunities are improved reconstitution, lower injection force, better suspension uniformity, device integration and longer dosing intervals.
  • A generic entrant would face complex injectable equivalence, release-profile and manufacturing challenges.
  • Signifor LAR is not eligible for a biosimilar pathway.
  • Patent exposure can continue through formulation, manufacturing and method-of-use claims after basic active-ingredient rights expire.
  • No standalone Signifor LAR revenue figure is generally disclosed by Novartis.
  • The strongest competitive position is likely created by the combination of polymer attributes, microsphere morphology, release performance and manufacturing know-how.

FAQs

Can Signifor LAR use a different PLGA grade?

Yes, but a different PLGA grade could change release kinetics, burst release, particle integrity and local tolerability. The substitution would require comparative formulation and regulatory evaluation.

Is pasireotide pamoate the same as pasireotide diaspartate?

No. Signifor LAR uses pasireotide pamoate in a depot formulation, while short-acting Signifor injection uses pasireotide diaspartate. The salts and dosage forms are not interchangeable on a simple mass basis.

Could a ready-to-use Signifor LAR product obtain separate market protection?

Potentially. Protection could arise from a device, container, reconstitution process, suspension-stability profile or differentiated dosing regimen, subject to patentability and regulatory requirements.

Would a generic Signifor LAR require clinical trials?

The required evidence would depend on the FDA pathway and the extent of formulation similarity. A conventional ANDA may require extensive pharmaceutical equivalence and bioequivalence evidence, while a materially different depot product could require additional clinical data under a 505(b)(2) pathway.

Which excipient is most commercially important in Signifor LAR?

PLGA is the most commercially important because it determines the depot structure and release profile. Sodium carboxymethylcellulose and poloxamer 188 are also important for reconstitution, suspension stability and injection performance.

References

  1. U.S. Food and Drug Administration. (2023). Signifor LAR (pasireotide pamoate) prescribing information. Novartis Pharmaceuticals Corporation. https://www.accessdata.fda.gov/drugsatfda_docs/label/

  2. U.S. Food and Drug Administration. (2018). FDA approves Signifor LAR for Cushing’s disease. https://www.fda.gov/

  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

  4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/---

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.